Reaction

Paraplegia reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,848 reports · 78 co-occurring drugs

As of the last recalculation, Paraplegia appears in 2,848 FAERS reports alongside 78 co-occurring drug terms. The strongest observed disproportionality signal is BUPIVACAINE (PRR 34.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Bupivacaine	44	34.9	35.1
Methylprednisolone Acetate	30	27.7	27.8
Rocuronium Bromide	26	16.3	16.3
Thiotepa	20	15.4	15.4
Iohexol	17	15.1	15.1
Sevoflurane	16	14.1	14.2
Cytarabine	102	12.8	12.9
Tizanidine Hydrochloride	31	12.7	12.7
Axicabtagene Ciloleucel	15	11.2	11.2
Enoxaparin Sodium	79	10.3	10.3
Lidocaine Hydrochloride And Epinephrine Bitartrate	70	9.8	9.8
Cefazolin	12	9.6	9.7
Lidocaine Hydrochloride	74	9.2	9.2
Cefazolin Sodium	15	9.1	9.1
Lidicaine	60	9.1	9.1
Burn Relief	60	9.1	9.1
Lidocaine Hydrochloride And Epinephrine	60	9.1	9.1
Fondaparinux Sodium	10	9.1	9.1
Lidocaine, Menthol	60	9.0	9.0
Carbamazepine	80	8.9	9.0
Lidocaine 4%	61	8.3	8.3
Lidocaine	61	7.8	7.8
Propofol	38	7.7	7.7
Alemtuzumab	20	7.6	7.6
Heparin Sodium	13	6.9	6.9
Itraconazole	11	6.9	6.9
Mercaptopurine	16	6.8	6.8
Fentanyl	86	6.5	6.6
Chlorthalidone	10	6.3	6.3
Midazolam	21	6.1	6.1
Midazolam Hydrochloride	22	6.0	6.0
Goserelin	11	6.0	6.0
Insulin	45	6.0	6.0
Ifosfamide	17	5.8	5.8
Interferon Beta-1B	15	5.7	5.7
Bleomycin Sulfate	8	5.7	5.7
Daptomycin	7	5.6	5.6
Baclofen	63	5.4	5.4
Levetiracetam In Sodium Chloride	54	5.2	5.2
Levetiracetam Oral	54	5.2	5.2
Levetiracetam Injection	54	5.2	5.2
Siponimod	6	4.9	4.9
Fingolimod Hcl	53	4.5	4.5
Interferon Beta-1A	116	4.5	4.5
Peginterferon Beta-1A	8	4.5	4.5
Clopidogrel Bisulfate	60	4.4	4.4
Dexamethasone 1.5 Mg	166	4.3	4.3
Dexamethasone	167	4.3	4.3
Brentuximab Vedotin	6	4.3	4.3
Efavirenz	6	3.9	3.9
Doxorubicin	47	3.9	3.9
Sevelamer Carbonate	6	3.8	3.8
Cladribine	5	3.8	3.8
Thalidomide	19	3.8	3.8
Ofatumumab	17	3.8	3.8
Vigabatrin	7	3.5	3.5
Etoposide	35	3.5	3.5
Dabrafenib	10	3.5	3.5
Natalizumab	84	3.4	3.5
Trametinib	11	3.3	3.3
Cisplatin	35	3.3	3.3
Abiraterone	6	3.2	3.2
Dimethyl Fumarate	52	3.1	3.1
Diroximel Fumarate	5	3.1	3.1
Abiraterone Acetate	17	3.0	3.0
Alteplase	6	2.9	2.9
Fentanyl Citrate	7	2.9	2.9
Temozolomide	8	2.8	2.8
Ocrelizumab	22	2.6	2.6
Nivolumab	34	2.6	2.6
Glatiramer Acetate	21	2.6	2.6
Ipilimumab	15	2.5	2.5
Vismodegib	3	2.5	2.5
Lutetium Lu 177 Vipivotide Tetraxetan	4	2.2	2.2
Leuprolide Acetate	23	2.2	2.2
Pazopanib Hydrochloride	8	2.2	2.2
Dalfampridine	18	1.8	1.8
Durvalumab	5	1.8	1.8

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.